Risankizumab

利生奇珠单抗

Report date: 2026/05/25 20:02:40

Base Information

Drug NameRisankizumab
Drug Alias Name瑞莎珠单抗risankizumab-rzaaSkyriziSKYRIZI喜开悦 +[7] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionInterleukin-23 subunit p19 inhibitors
TargetsInterleukin-23 subunit p19
Therapy Area/IndicationsPlaque psoriasisPsoriasisDermatitis +[10] 
Global Approved IndicationsPlaque psoriasisPsoriasisCrohn Disease +[4] 
Approved Indications in ChinaCrohn Disease
Original Approved Country/TerritoryJapan
Original Approved Date2019/03/26
Country/TerritoryCzechiaBelgiumBosnia and Herzegovina +[56] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesC.H. Boehringer Sohn Ag & Co. Kg
China Registration ClassN/A

Develop Information

Active CompaniesTaizhou Hospital Of Zhejiang ProvinceUniversity Medical Center GroningenBoehringer Ingelheim Pharma Gmbh & Co Kg +[8] 
Inactive CompaniesC.H. Boehringer Sohn Ag & Co. Kg
Active IndicationsPlaque psoriasisPsoriasisCrohn Disease +[7] 
Inactive IndicationsDermatitisAsthmaSpondylitis, Ankylosing

Other Information

ATC CodeL04AC18
Related LinksWikipediaDrugBankKEGG